Methotrexate in ocular manifestations of Behcet's disease: A longitudinal study up to 15 years

International Journal of Rheumatic Diseases

Volumn 16, Issue 5, 2013, Pages 568-577

  Davatchi, Fereydoun ^a   Shams, Hormoz ^a   Shahram, Farhad ^a   Nadji, Abdolhadi ^a   Chams Davatchi, Cheyda ^a   Sadeghi Abdollahi, Bahar ^a   Faezi, Tahereh ^a   Akhlaghi, Massoomeh ^a   Ashofteh, Farimah ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Behcet's disease; Cytotoxic therapy; Methotrexate; Ocular manifestations; Steroid therapy

Indexed keywords

METHOTREXATE; PREDNISOLONE;

ARTICLE; BEHCET DISEASE; CATARACT; DISEASE ACTIVITY; DRUG EFFICACY; EYE INFLAMMATION; FOLLOW UP; HUMAN; IRIDOCYCLITIS; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; RETINA VASCULITIS; TOTAL ADJUSTED DISEASE ACTIVITY INDEX; TOTAL INFLAMMATORY ACTIVITY INDEX; UVEITIS; VISUAL ACUITY;

BEHCET'S DISEASE; CYTOTOXIC THERAPY; METHOTREXATE; OCULAR MANIFESTATIONS; STEROID THERAPY;

ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; CAPSULE OPACIFICATION; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; LONGITUDINAL STUDIES; METHOTREXATE; PREDNISOLONE; RECOVERY OF FUNCTION; REGISTRIES; RETINAL VASCULITIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UVEITIS, ANTERIOR; UVEITIS, POSTERIOR; VISUAL ACUITY;

EID: 84886585953     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12139     Document Type: Article

References (46)

1. Mamo JG, Azzam SA (1970) Treatment of Behcet's disease with chlorambucil. Arch Ophthalmol 84, 446-50.
2. Bietti GB, Cerulli L, Pivetti-Pezzi P (1976) Behcet's disease and immunosuppressive treatment. Our personal experience. Mod Probl Ophthalmol 16, 314-23.
3. Tricoulis D (1976) Treatment of Behcet's disease with chlorambucil. Br J Ophthalmol 60, 55-7.
4. Mamo JG (1976) Treatment of Behcet's disease with chlorambucil. A follow-up report. Arch Ophthalmol 94, 580-3.
5. BenEzra D, Nussenblatt R (1978) Ocular manifestations of Behcet's disease. J Oral Pathol 7, 431-5.
6. Benamour G, Bonnet M (1978) Immunosupressive agents and Behcet's syndrome: critical analysis of results. Adv Ophthalmol 36, 118-29.
7. Bonnet M (1981) Immunosuppressive therapy of Behcet's syndrome. Long term follow-up evaluation. J Fr Ophtalmol 4, 455-64.
8. Tabara KF (1983) Chlorambucil in Behcet's disease. A reappraisal. Ophthalmology 90, 906-8.
9. Palmer RG, Dore CJ, Denman AM (1984) Chlormbucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative. Lancet 8371, 246-9.
10. Davatchi F, Baygan F, Chams H, Chams C (1984) Cyclophosphamide in the treatment of the ocular manifestations of Behcet's disease. J Rheumatol 11, 404-5.
11. Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G (1985) Prognosis in Behcet's disease. Ann Ophthalmol 17, 20-5.
12. Benezra D, Cohen E (1986) Treatment and visual prognosis in Behcet's disease. Br J Ophthalmol 70, 589-92.
13. Davatchi F, Chams H, Shahram F et al. (1988) Pulse cyclophosphamide in ophthalmologic manifestations of Behcet's disease. Ferraz de Oliveira LN (ed.) Ophthalmology Today, pp 387-91. Excerpta Medica, S.O.I., International Congress series 803, Amsterdam.
14. Benezra D, Cohen E, Chajek T et al. (1988) Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 20, 136-43.
15. Schilling H, Bornfeld N, Windeck R, Wessing A, Kirch W (1990) Cytotoxic and immunosuppressive treatment of ocular Behcet's syndrome. Klin Monatsbl Augenheilkd 196, 62-9.
16. Tessler HH, Jennings T (1990) High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 74, 353-7.
17. Davatchi F, Shahram F, Chams H et al. (1991) Pulse cyclophosphamide in ophthalmological manifestations of Behcet's disease. O'Duffy JD, Kokmen E (eds) Behcet's Disease Basic and Clinical Aspects, pp 555-61. Marcel Decker Inc., New York.
18. Fain O, Thi Huong Du L, Wechsler B et al. (1991). Pulse cyclophosphamide in Behcet's disease. O'Duffy JD, Kokmen E (eds) Behcet's Disease, Basic and Clinical Aspects, pp 569-73. Marcel Decker Inc., New York.
19. Hamza M, Meddeb S, Mili I, Ouertani A (1992) Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet's disease. Preliminary results with the use of new criteria of evaluation. Ann Med Interne 143, 438-41.
20. Davatchi F (1998). Neuro-ophthalmic Behcet's. Torralba TP, Amante CM, Victorio-Navarra STG (eds) APLAR 3rd Symposium on the Therapy of Rheumatic Diseases, pp 16-7. Excerpta Medica Asia Ltd., Hong Kong.
21. Shahram F, Davatchi F, Chams H, Akbarian M, Gharibdoost F (1993). Low dose pulse cyclophosphamide (LDP) in ophthalmologic lesions of Behcet's disease. Godeau P, Wechsler B (eds) Behcet's Disease, pp 683-6. Elsevier Science Publishers B.V, Amsterdam.
22. Davatchi F, Shahram F, Chams H et al. (1998) Pulse cyclophosphamide for ocular manifestations of Behcet's disease. Cohort study on 283 patients. Rev Rheum (Engl Ed) 65, 692.
23. Shahram F, Davatchi F, Chams H, Akbarian M (1997). Cyclosporin in severe ocular lesions of Behcet's disease. Hamza M (ed.) Behcet's Disease, pp 421-3. Pub Adhoua, Tunis.
24. Davatchi F, Shahram F, Chams H et al. (2000) Azathioprine for the treatment of ophthalmological lesions of Behcet's disease. In Bang D, Lee ES, Lee S (eds) Behcet's Disease, pp 898-900. Design Mecca Publishing Co., Seoul, Korea.
25. Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet's disease-an update. Semin Arthritis Rheum 30, 299-312.
26. Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO (2001) Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 9, 219-29.
27. Shahram F, Davatchi F, Chams H et al. (2003) Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Behcet's disease. A preliminary report. Adv Exp Med Biol 528, 571-3.
28. Davatchi F, Shams H, Shahram F (2009) Longitudinal study of chlorambucil in ocular manifestations of Behcet's disease. Iranian J Ophthalmol 21, 3-14.
29. Davatchi F, Shams H, Shahram F et al. (2005) Management of ocular manifestations of Behcet's disease with cytotoxic drugs. APLAR J Rheum 8, 119-23.
30. Davatchi F (2004) New and innovative therapies for Behcet's disease. APLAR J Rheumatol 7, 141-5.
31. Davatchi F, Shahram F, Chams-Davatchi C et al. (2010) How to deal with Behcet's disease in daily practice. Int J Rheum Dis 13, 105-16.
32. Shahram F, Davatchi F, Chams H, Akbarian M, Chams C, Tebbi ME (1990). Methotrexate in ocular Behcet disease, Preliminary report, Abstract FP-23. First APLAR Symposium on the Therapy of Rheumatic Diseases, Seoul, Korea.
33. Shahram F, Davatchi F, Chams H, Akbarian M, Chams C (1992). Pulse cyclophosphamide versus pulse methotrexate in ophthalmological manifestations of Behcet's disease. Nasution AR, Darmawan J, Isbagio H (eds) APLAR Rheumatology, pp 119-22. Churchill Livingstone, Tokyo.
34. Shahram F, Davatchi F, Chams H, Akbarian M, Gharibdoost F (1993) Comparing 3 methods of Cytotoxic therapy in ophthalmologic lesions of Behcet's disease. Godeau P, Wechsler B. Behcet's Disease (eds) pp 635-40. Elsevier Science Publishers B.V., Amsterdam.
35. Davatchi F, Shahram F, Gharibdoost F et al. (1996) Outcome analysis of ocular lesions in Behcet's disease with 6 different therapeutic methods. Arthritis Rheum 39, S217.
36. Davatchi F, Shahram F, Chams H et al. (1998) Methotrexate for ocular lesions of Behcet's disease. Cohort study on 262 patients. Arthritis Rheum 41, S356.
37. Davatchi F, Shahram F, Chams H et al. (2003) High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv Exp Med Biol 528, 579-84.
38. Davatchi F (2000) Treatment of ocular manifestations of Behcet's Disease. Proceedings, 9th Asia Pacific League of Associations for Rheumatology Congress. Beijing, China, pp 174-6.
39. Shahram F, Chams H, Davatchi F, Nadji A, Jamshidi AR, Akbarian M (2000). Intermediate term results of combination therapy with low dose pulse cyclophosphamide and methotrexate in ocular lesions of Behcet's disease. Bang D, Lee ES, Lee S (eds) Behcet's Disease, pp 453-6. Design Mecca Publishing, Seoul, Korea.
40. Davatchi F (2002) Treatment of ocular manifestations of Behcet's Disease. Proceedings, 10th Asia Pacific League of Associations for Rheumatology Congress. Thailand, pp 28-32.
41. Davatchi F (2003) Treatment of ocular manifestations of Behcet's disease. Adv Exp Med Biol 528, 487-91.
42. Shafaie N, Shahram F, Chams H, Davatchi F, Nadji A, Akbarian M (1998). Methotrexate in the treatment of ocular lesions of Behcet's disease in children. Bang D, Lee ES, Lee S (eds) Behcet's Disease, pp 773-9. Design Mecca Publishing, Seoul, Korea.
43. Ben Ezra D, Forrester JV, Nussenblatt RB (1991). Uveitis Scoring System. Sandoz Ltd and Springer Verlag, Heidelberg, Germany.
44. Davatchi F, Shahram F, Chams H et al. (2003) The influence of the delay of aggressive treatment on the vision and its outcome in Behcet's disease. Adv Exp Med Biol 528, 493-4.
45. Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41, 61-70.
46. Davatchi F, Shams H, Rezaipoor M et al. (2010) Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13, 246-52.